The U.S. acromegaly treatment market size was estimated at USD 571.3 million in 2024 and is projected to reach USD 977.2 million by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This is attributed to the rising prevalence of acromegaly and earlier diagnoses, coupled with advancements in diagnostic tools such as MRI and IGF-1 tests, improved awareness, and a better understanding of the disease’s symptoms.
Technological advances in diagnostics and the adoption of personalized treatment regimens are expected to help early detection and adherence. Strong healthcare infrastructure, insurance support, and multidisciplinary care teams are further expected to support market expansion.
Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.
This product will be delivered within 2 business days.
Technological advances in diagnostics and the adoption of personalized treatment regimens are expected to help early detection and adherence. Strong healthcare infrastructure, insurance support, and multidisciplinary care teams are further expected to support market expansion.
Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.
U.S. Acromegaly Treatment Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. acromegaly treatment market report based on drug class, and distribution channel:Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Somatostatin Analogues (SSAs)
- Growth Hormone Receptor Antagonists (GHRAs)
- Dopamine Agonists
- Other Drug Types (Combination Therapies, Pipeline Drugs)
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Acromegaly Treatment Market Variables, Trends & Scope
Chapter 4. Consumer Behavior Analysis
Chapter 5. U.S. Acromegaly Treatment Market: Drug Class Estimates & Trend Analysis
Chapter 6. U.S. Acromegaly Treatment Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. U.S. Acromegaly Treatment Market - Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Novartis AG
- Ipsen Pharma
- Sun Pharmaceutical Industries Ltd
- Chiasma, Inc.
- Crinetics Pharmaceuticals
- WOCKHARDT
- Pfizer Inc.
- Ionis Pharmaceuticals, Inc.
- Teva Pharmaceuticals
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 80 |
Published | July 2025 |
Forecast Period | 2024 - 2033 |
Estimated Market Value ( USD | $ 571.3 Million |
Forecasted Market Value ( USD | $ 977.2 Million |
Compound Annual Growth Rate | 6.2% |
Regions Covered | United States |
No. of Companies Mentioned | 9 |